Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Breast Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
48 drugs · 217 active trials
17 drugs · 330 active trials
43 drugs · 1,254 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 11 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Aromatase Inhibitor | Phase 4 | Phase 4 | 11 | 5 | 2 | 22 | 0 | — | — | Nov 7, 2008 |
| Pegfilgrastim | Phase 4 | Phase 4 | 5 | 2 | 13 | 52 | 0 | — | — | 2001-10 |
| Dexamethasone | Phase 4 | Phase 4 | 5 | 3 | 5 | 23 | 0 | — | — | 2004-08 |
| Carboplatin/Paclitaxel Regimen | Phase 4 | Phase 4 | 4 | 1 | 2 | 8 | 0 | — | — | 2007-12 |
| Lenvatinib | Phase 4 | Phase 4 | 3 | 0 | 0 | 9 | 0 | — | — | 2016-12 |
| Filgrastim | Phase 4 | Phase 4 | 1 | 1 | 12 | 72 | 0 | — | — | 1991-11 |
| Sunitinib | Phase 4 | Phase 4 | 1 | 0 | 0 | 15 | 0 | — | — | Mar 1, 2006 |
| Zoledronic Acid | Phase 4 | Phase 4 | 0 | 0 | 24 | 46 | 0 | — | — | 1999-06 |
| Pazopanib | Phase 4 | Phase 4 | 0 | 0 | 0 | 10 | 0 | — | — | 2007-01 |
| Paclitaxel Liposome | Phase 4 | Phase 4 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-05 |
| Hormone Therapy | Phase 3 | Phase 3 | 21 | 12 | 11 | 36 | 0 | — | — | 1989-05 |
| Durvalumab | Phase 3 | Phase 3 | 20 | 8 | 4 | 43 | 0 | — | — | Dec 19, 2013 |
| Nivolumab | Phase 3 | Phase 3 | 19 | 8 | 1 | 50 | 0 | — | — | Nov 15, 2013 |
| Atezolizumab | Phase 3 | Phase 3 | 18 | 6 | 11 | 60 | 0 | — | — | Mar 12, 2015 |
| Vinorelbine | Phase 3 | Phase 3 | 16 | 9 | 34 | 110 | 0 | — | — | 1998-10 |
| Cisplatin | Phase 3 | Phase 3 | 13 | 4 | 11 | 76 | 0 | — | — | Sep 26, 1995 |
| Camrelizumab | Phase 3 | Phase 3 | 10 | 6 | 2 | 20 | 0 | — | — | Apr 27, 2016 |
| Aldesleukin | Phase 3 | Phase 3 | 9 | 7 | 1 | 31 | 0 | — | — | 1995-02 |
| Adebrelimab | Phase 3 | Phase 3 | 9 | 5 | 1 | 12 | 0 | — | — | Mar 30, 2020 |
| Disitamab Vedotin | Phase 3 | Phase 3 | 9 | 6 | 1 | 10 | 0 | — | — | Mar 1, 2023 |
| Ipatasertib | Phase 3 | Phase 3 | 8 | 3 | 3 | 19 | 0 | — | — | Feb 17, 2015 |
| Avelumab | Phase 3 | Phase 3 | 8 | 1 | 1 | 15 | 0 | — | — | Jun 17, 2016 |
| Zanidatamab | Phase 3 | Phase 3 | 8 | 7 | 1 | 9 | 0 | — | — | Mar 1, 2010 |
| Metformin | Phase 3 | Phase 3 | 6 | 3 | 4 | 36 | 0 | — | — | 2008-03 |
| Niraparib | Phase 3 | Phase 3 | 6 | 1 | 1 | 17 | 0 | — | — | Feb 25, 2014 |
| Bicalutamide | Phase 3 | Phase 3 | 6 | 2 | 1 | 12 | 0 | — | — | Mar 23, 2007 |
| Veliparib | Phase 3 | Phase 3 | 4 | 1 | 2 | 25 | 0 | — | — | 2007-08 |
| Leuprolide | Phase 3 | Phase 3 | 4 | 2 | 6 | 16 | 0 | — | — | 1993-06 |
| Enzalutamide | Phase 3 | Phase 3 | 3 | 1 | 1 | 15 | 0 | — | — | Apr 30, 2012 |
| Retifanlimab | Phase 3 | Phase 3 | 3 | 2 | 1 | 6 | 0 | — | — | Feb 27, 2015 |
| Serplulimab | Phase 3 | Phase 3 | 3 | 1 | 1 | 3 | 0 | — | — | Apr 17, 2020 |
| Aspirin | Phase 3 | Phase 3 | 2 | 1 | 2 | 7 | 0 | — | — | 2008-07 |
| Sirolimus | Phase 3 | Phase 3 | 2 | 0 | 1 | 6 | 0 | — | — | 2006-12 |
| Celecoxib | Phase 3 | Phase 3 | 1 | 1 | 3 | 24 | 0 | — | — | 2000-06 |
| Sorafenib | Phase 3 | Phase 3 | 1 | 1 | 1 | 15 | 0 | — | — | 2004-02 |
| Melphalan | Phase 3 | Phase 3 | 1 | 1 | 1 | 13 | 0 | — | — | 1991-12 |
| Triptorelin | Phase 3 | Phase 3 | 1 | 1 | 6 | 12 | 0 | — | — | 2003-08 |
| Taselisib | Phase 3 | Phase 3 | 1 | 0 | 1 | 7 | 0 | — | — | Jul 16, 2013 |
| Carmustine | Phase 3 | Phase 3 | 1 | 1 | 2 | 5 | 0 | — | — | 1991-12 |
| Adjuvant Chemotherapy | Phase 3 | Phase 3 | 1 | 1 | 1 | 4 | 0 | — | — | 2007-12 |
| Mitomycin | Phase 3 | Phase 3 | 1 | 0 | 1 | 2 | 0 | — | — | 1998-07 |
| Chemoradiotherapy | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | May 14, 2024 |
| Taxane Compound | Phase 3 | Phase 3 | 1 | 0 | 1 | 1 | 0 | — | — | Mar 9, 2027 |
| Gefitinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 20 | 0 | — | — | 2001-04 |
| Buparlisib | Phase 3 | Phase 3 | 0 | 0 | 3 | 17 | 0 | — | — | 2008-11 |
| Etoposide | Phase 3 | Phase 3 | 0 | 0 | 1 | 15 | 0 | — | — | 1991-11 |
| Mitoxantrone | Phase 3 | Phase 3 | 0 | 0 | 3 | 7 | 0 | — | — | 1992-07 |
| Ibandronic Acid | Phase 3 | Phase 3 | 0 | 0 | 4 | 6 | 0 | — | — | 2004-06 |
| Taxol | Phase 3 | Phase 3 | 0 | 0 | 3 | 5 | 0 | — | — | 1999-03 |
| Abiraterone Acetate | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2008-10 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.